Arianna Gentilini

Postdoctoral Researcher @ImperialBiz | PhD @LSEHealthPolicy

[LSE Health Policy @LSEHealthPolicy]

𝐖𝐡𝐲 𝐂𝐨𝐫𝐫𝐮𝐩𝐭𝐢𝐨𝐧 𝐏𝐞𝐫𝐬𝐢𝐬𝐭𝐬 𝐢𝐧 𝐭����𝐞 𝐄𝐮𝐫𝐨𝐩𝐞𝐚𝐧 𝐇𝐞𝐚𝐥𝐭𝐡 𝐒𝐞𝐜𝐭𝐨𝐫 💰

Corruption drains budgets, erodes trust & fuels inequality in Europe’s health systems.

Why does it persist?

👉 Read Iva Parvanova’s blog here: https://t.co/2MqPBJNG39

[Arianna Gentilini @agentilini_]

@mylene_lagarde @LSEHealthPolicy Congratulations, Mylene!! Very well deserved :)

[Elisabetta De Cao @elisabettadecao]

🚨 Job Alert 🚨
4-year postdoc position to work on my ERC project HARSH - Uncovering the Roots of Harsh Parenting.
📍 Dep. of Economics @DSE_Unibo, Bologna, Italy 🇮🇹
📅 Deadline: March 14, 2025
💡 Learn more and apply here: https://t.co/Ts3jhFQRdu
#econtwitter #econjobmarket #ejm

[Kristina Jenei @kjmeetswrld]

✨Chuffed to have won the best presentation at @UUUIPS Winter Meeting.

Was a great time hearing about different projects at all different cross-sections and meet the policy faculty.

@LSEHealthPolicy

[Arianna Gentilini @agentilini_]

@LSEHealthPolicy @ImperialBiz @consiliumsci

[Arianna Gentilini @agentilini_]

1/ 📢 New paper out today in the Eur J Health Econ with Alina Rana!

We reviewed patient submissions to 15 NICE Highly Specialised Technology appraisals to see how patient voices are considered in decision-making.

Full article below 👇🏼
https://t.co/CenvUuvJcv

[Arianna Gentilini @agentilini_]

6/ 📌 While NICE considers many patient-relevant issues, there's room for improvement to ensure all concerns are considered. Increasing diversity of viewpoints and clarifying the management of conflicts of interest can further strengthen the process.

[LSE Health Policy @LSEHealthPolicy]

New paper by @IvaParvanova01 & @mylene_lagarde examines how survey wording affects bribery rates in #healthcare.💰Loaded (corruption-linked) vs neutral (payments/gifts) wording reveals notable differences across countries.🔗https://t.co/zqE1C2efUW
#InternationalAntiCorruptionDay

[Dario Trapani @darioT_]

In this latest work, @KanavosPG et al from @LSEHealthPolicy provide a validation exercise on the use of @myESMO #MCBS as a tool to aid in decision-making for #cancer drugs. #HTA

A next step toward #value -based healthcare, more to come on this! ✔️

@VriesElisabeth

[LSE Health Policy @LSEHealthPolicy]

🚨New Research by @IvaParvanova01 & @agentilini_ on the EU's 24 COI regulation in JCA. 🌟
📊 Key findings:
✔️Progress in transparency for EU-wide HTAs.
✔️Concerns on expert diversity & COI enforcement.
✔️Recs for stronger accountability.
🔗Read now👇https://t.co/kICJxRrSGG

[Arianna Gentilini @agentilini_]

New article w/ @IvaParvanova01 out in @BMJ_Open! 👇🏻

[Imperial Business School @ImperialBiz]

Congratulations to Dr Arianna Gentilini [@agentilini_] whose paper 'Managing experts’ conflicts of interest in the EU Joint Clinical Assessment' has been published in @BMJ_Open 👏 👏 👏

Read the paper: https://t.co/FS5nBhJWyz

#IBResearch

[Iva Parvanova @IvaParvanova01]

🚨@agentilini_ and I analyze the new COI regulation for EU HTA (#JCA) @BMJ_Open, key points:
✍️No guidance for disclosing the size of financial interests
⚖️No COI mitigation for experts from conflicted orgs or conflicted experts (esp for rare diseases)

👉https://t.co/cg4JpTZyUD

[Investigate Europe @investigate_eu]

UK patient organisations took €20m from drug companies in 2022, followed by groups in Belgium, France, Italy and Germany. In a first Europe-wide study, our investigation reveals 11,000+ payments made by pharma industry to advocacy groups and charities: https://t.co/nKL7wY8HFv

[Kristina Jenei @kjmeetswrld]

Check out our study
👇👇👇

cc: @VPrasadMDMPH @agentilini_ @AlysonHaslam

[Veronika Wirtz (@verowirtz.bsky.social) @VeroWirtz]

Access to medicines is a critical indicator of progress towards the SDGs and should not be dropped. Read our recommendations how to strengthen investment in measurement #IAEG Inter-Agency —Expert Group on #SDGs Indicators (IAEG-SDGs) @kjmeetswrld @UNStats https://t.co/llgO3aYhA3